RBC Capital analyst Joe Kim lowered the firm’s price target on Mirum Pharmaceuticals (MIRM) to $128 from $130 and keeps an Outperform rating on the shares. The company’s pre-reported Q4 product revenue and guidance reflect strong and durable growth in Livmarli and bile acid medicine, and with multiple registrational datapoints over the next 12 months that could add $2B to its top-line, the firm sees further stock upside, the analyst tells investors in a research note.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MIRM:
- Mirum Pharmaceuticals price target raised to $125 from $98 at Stifel
- Mirum Pharmaceuticals: Livmarli-Driven Outperformance and Catalyst-Rich Pipeline Underpin Buy Rating
- Mirum Pharmaceuticals price target lowered to $132 from $140 at Citizens
- Mirum Pharmaceuticals files to sell 8.96M shares of common stock for holders
- Is MIRM a Buy, Before Earnings?